Best Practice & Research Clinical Rheumatology
Volume 20, Issue 2 , Pages 279-300, April 2006

Current management of juvenile idiopathic arthritis

  • Carol A. Wallace, MD (Associate Professor, Pediatrics)

      Affiliations

    • Corresponding Author InformationTel.: +1 206 987 4448; Fax: +1 206 987 5060.

Division of Immunology, Rheumatology and Infectious Diseases, Children's Hospital and Regional Medical Center, University of Washington School of Medicine, 4800 Sandpoint Way NE MS-B-6583, Seattle, WA 98105, USA

The goal of juvenile idiopathic arthritis (JIA) treatment is to achieve remission of disease. The absence of a full understanding of the disease pathogenesis for JIA hinders the development of truly effective treatment approaches. Further, the lack of clear knowledge regarding the mechanisms of action of rheumatologic medications and the existence of few randomized controlled trials leaves clinicians with very little evidence upon which to base decisions regarding the best timing, dosages or combinations of medications to be used for fully effective treatment of JIA. There is now a shift in treatment focus from that of chasing failure (gradual add-on approach to the use of medications) to one of early aggressive combination treatment. This chapter will discuss the current approaches to medical management of JIA and the medications currently available for use. JIA treatment is a vast, rich area in need of research.

Key words: JIA, treatment, medications, remission

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1521-6942(05)00131-2

doi:10.1016/j.berh.2005.11.008

Best Practice & Research Clinical Rheumatology
Volume 20, Issue 2 , Pages 279-300, April 2006